Sven Ante Lundberg - Net Worth and Insider Trading
Sven Ante Lundberg Net Worth
The estimated net worth of Sven Ante Lundberg is at least $55 Million dollars as of 2024-11-28. Sven Ante Lundberg is the Chief Scientific Officer of CRISPR Therapeutics AG and owns about 1,010,834 shares of CRISPR Therapeutics AG (CRSP) stock worth over $51 Million. Sven Ante Lundberg is also the President, CEO & PFO of Merus NV and owns about 78,071 shares of Merus NV (MRUS) stock worth over $4 Million. Details can be seen in Sven Ante Lundberg's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Sven Ante Lundberg has not made any transactions after 2022-11-03 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Sven Ante Lundberg
Sven Ante Lundberg Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Sven Ante Lundberg owns 3 companies in total, including Merus NV (MRUS) , CRISPR Therapeutics AG (CRSP) , and Vor Biopharma Inc (VOR) .
Click here to see the complete history of Sven Ante Lundberg’s form 4 insider trades.
Insider Ownership Summary of Sven Ante Lundberg
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| MRUS | Merus NV | 2022-11-03 | director & President & CEO & PFO |
| CRSP | CRISPR Therapeutics AG | 2016-10-24 | Chief Scientific Officer |
| VOR | Vor Biopharma Inc | 2021-02-04 | director |
Sven Ante Lundberg Latest Holdings Summary
Sven Ante Lundberg currently owns a total of 2 stocks. Among these stocks, Sven Ante Lundberg owns 1,010,834 shares of CRISPR Therapeutics AG (CRSP) as of October 24, 2016, with a value of $51 Million and a weighting of 93.61%. Sven Ante Lundberg also owns 78,071 shares of Merus NV (MRUS) as of November 3, 2022, with a value of $4 Million and a weighting of 6.39%.
Latest Holdings of Sven Ante Lundberg
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| CRSP | CRISPR Therapeutics AG | 2016-10-24 | 1,010,834 | 50.84 | 51,390,801 |
| MRUS | Merus NV | 2022-11-03 | 78,071 | 44.97 | 3,510,853 |
Holding Weightings of Sven Ante Lundberg
Sven Ante Lundberg Form 4 Trading Tracker
According to the SEC Form 4 filings, Sven Ante Lundberg has made a total of 0 transactions in CRISPR Therapeutics AG (CRSP) over the past 5 years. The most-recent trade in CRISPR Therapeutics AG is the acquisition of 400 shares on October 24, 2016, which cost Sven Ante Lundberg around $5,600.
According to the SEC Form 4 filings, Sven Ante Lundberg has made a total of 4 transactions in Merus NV (MRUS) over the past 5 years, including 4 buys and 0 sells. The most-recent trade in Merus NV is the acquisition of 14,706 shares on November 3, 2022, which cost Sven Ante Lundberg around $211,472.
Insider Trading History of Sven Ante Lundberg
- 1
Sven Ante Lundberg Trading Performance
GuruFocus tracks the stock performance after each of Sven Ante Lundberg's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Sven Ante Lundberg is -6.18%. GuruFocus also compares Sven Ante Lundberg's trading performance to market benchmark return within the same time period. The performance of stocks bought by Sven Ante Lundberg within 3 months outperforms 1 times out of 5 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Sven Ante Lundberg's insider trading performs compared to the benchmark.
Performance of Sven Ante Lundberg
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 2.56 | | | | | |
| Relative Return to S&P 500(%) | 1.14 | | | | | |
Sven Ante Lundberg Ownership Network
Sven Ante Lundberg Owned Company Details
What does Merus NV do?
Who are the key executives at Merus NV?
Sven Ante Lundberg is the director & President & CEO & PFO of Merus NV. Other key executives at Merus NV include Chief Accounting Officer Harry Shuman , EVP & General Counsel Peter B. Silverman , and other: See Explanation of Responses Biotechnology Value Fund L P .
Merus NV (MRUS) Insider Trades Summary
Over the past 18 months, Sven Ante Lundberg made no insider transaction in Merus NV (MRUS). Other recent insider transactions involving Merus NV (MRUS) include a net sale of 20,815 shares made by Harry Shuman , and a net sale of 94,386 shares made by Peter B. Silverman .
In summary, during the past 3 months, insiders sold 0 shares of Merus NV (MRUS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 115,201 shares of Merus NV (MRUS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 115,201 shares.
Merus NV (MRUS)'s detailed insider trading history can be found in Insider Trading Tracker table.
Merus NV Insider Transactions
Sven Ante Lundberg Mailing Address
Above is the net worth, insider trading, and ownership report for Sven Ante Lundberg. You might contact Sven Ante Lundberg via mailing address: C/o Crispr Therapeutics Ag, 200 Sidney Street, Cambridge Ma 02139.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
